Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Insight into the mechanism of laquinimod action.
Molecular characterization of a peripheral receptor for cannabinoids.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
NOVANTRONE. mitoXANTRONE for injection concentrate
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.

Pages